Analyze Catalogue Methodology Blog Pro Access

⚡ Interrogation des APIs scientifiques en cours…

The quality score for scientific publications. 100% free, 100% independent.

Navigation

Home
Analyze an article
Methodology
Blog
My account

Transparency

Our independence
Methodological transparency
Pro Access
Contact us
Legal notice
Privacy
ToU
ToS
Glossary

Developers

Public API
GitHub

Free score, forever.

D (44/100) — Peu fiable | Maini R et al. | Publi-Score

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Maini R et al.·The Lancet·Dec 1999·PMID 10622295

Authors' conclusion

Positive

Does not affect the score

Publi-Score

44/100

UnreliableLast updated: 4/18/2026

Fidelity

Abstract only65% concordance × 24/26 subcriteria

Category breakdown

Total raw score46.0/100

Integrity coefficient

A. Authors' integrity

COI declaration

0.40

Funding independence

0.60

Coeff. authors = avg(0.40, 0.60) = 0.50

B. Editorial process

Peer review

1.00

Submission→accept. delay

0.90

Coeff. editorial = avg(1.00, 0.90) = 0.95

min(0.50, 0.95) = 0.50← lowest dominates

🚫

Alert signal : eoc → Coefficient forced to 0.3

Expression of Concern published

Final coefficient : 0.50

Final score = 46.0/52.8 × 0.50 × 100 = 44/100

Save

📄 Export PDF

PubMed DOI

Twitter/X LinkedIn

Contribute

Actions

Analyze another article View the methodology

Information

PMID

10622295

DOI

10.1016/s0140-6736(99)05246-0

Mode

🔬 Partial AI (abstract)

Grid

v1.1

Scored on

4/18/2026

Similar publications

C52/100

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Schmid P — 2018 · The New England journal of medicine

C51/100

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS — 2017 · The New England journal of medicine

C49/100

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Eggermont AM — 2016 · The New England journal of medicine

C48/100

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Piccart-Gebhart MJ — 2005 · The New England journal of medicine